person · Reporting owner

Godshall Douglas Evan

Disclosed activity across 3 companies

Tapewire entity: 90381
SEC CIK: 0001404227

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
IMMUNIC, INC.VTL · Entity 6306	Director	September 19, 2018	September 21, 2018

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

IMMUNIC, INC.

Report date September 19, 2018 · Filed September 21, 2018

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Reported balance After 2018-09-19 transaction · row 1 1 source row Row 1 · 2018-09-19 · Sale · Disposed 69,375 · Balance 0 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.34 to $0.35. The reporting person undertakes to provide Vital Therapies, Inc., any security holder of Vital Therapies, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price range set forth in this footnote (1) to this Form 4.

Filing footnotes · ownership attribution and instrument terms

F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.34 to $0.35. The reporting person undertakes to provide Vital Therapies, Inc., any security holder of Vital Therapies, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price range set forth in this footnote (1) to this Form 4.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

EyePoint, Inc.

Report date June 22, 2021 · Filed June 23, 2021

Section 16 reporting ended · disclosed 2021-06-23. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	8,016	Reported balance After 2021-06-22 transaction · row 1 1 source row Row 1 · 2021-06-22 · Exercise / conversion · Acquired 2,500 · Balance 8,016
Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	0	Reported balance After 2021-06-22 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2021-06-22 · Exercise / conversion · Acquired 2,500 · Balance 0 F1: The grants were approved by the Compensation Committee on February 9, 2021, subject to stockholder approval of an amendment to increase the number of shares in the Company's 2016 Plan. The shareholders approved the amendment on June 22, 2021. F2: The Restricted Stock grant vested immediately upon Mr. Godshall's departure from the Board on June 22, 2021.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.13 · Expires 2023-06-22	Direct	11,000	Reported balance After 2021-06-22 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2021-06-22 · Grant · Acquired 11,000 · Balance 11,000 F1: The grants were approved by the Compensation Committee on February 9, 2021, subject to stockholder approval of an amendment to increase the number of shares in the Company's 2016 Plan. The shareholders approved the amendment on June 22, 2021. F3: The option to purchase vested immediately upon Mr. Godshall's departure from the Board on June 22, 2021.

Filing footnotes · ownership attribution and instrument terms

F1: The grants were approved by the Compensation Committee on February 9, 2021, subject to stockholder approval of an amendment to increase the number of shares in the Company's 2016 Plan. The shareholders approved the amendment on June 22, 2021.

F2: The Restricted Stock grant vested immediately upon Mr. Godshall's departure from the Board on June 22, 2021.

F3: The option to purchase vested immediately upon Mr. Godshall's departure from the Board on June 22, 2021.

Shockwave Medical, Inc.

Report date May 31, 2024 · Filed May 31, 2024

Section 16 reporting ended · disclosed 2024-05-31. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2024-05-31 transaction · row 1 1 source row Row 1 · 2024-05-31 · Disposition to issuer · Disposed 151,629 · Balance 0 F1: This Form 4 reports the disposition of securities pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 4, 2024, by and among the Issuer, Johnson & Johnson ("J&J"), and Sweep Merger Sub, Inc., a wholly owned subsidiary of J&J ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), effective as of the effective time of the Merger (the "Effective Time"), with the Issuer surviving the Merger as a wholly owned subsidiary of J&J. As a result of the Merger, at the Effective Time, each outstanding share of common stock, par value $0.001 per share, of the Issuer ("Common Stock") outstanding immediately prior to the Effective Time (excluding Excluded Shares and any Dissenting Company Shares, each as defined in the Merger Agreement) was automatically converted into the right to receive $335.00 in cash (the "Merger Consideration"), F2: (Continued from Footnote 1) without interest and less any applicable withholding taxes. Additionally, pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit ("RSU") outstanding immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive a cash amount, without interest and less any applicable withholding taxes, equal to the product of (i) the aggregate number of shares of Common Stock underlying such RSU immediately prior to the Effective Time and (ii) the Merger Consideration.
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $3.42 · Expires 2027-05-09	Direct	Reported balance After 2024-05-31 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2024-05-31 · Disposition to issuer · Disposed 294,799 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, with a per share exercise price that was less than the Merger Consideration, was cancelled and converted into the right to receive a cash amount, without interest and less any applicable withholding taxes, equal to the product of (i) the aggregate number of shares of Common Stock underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option.
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $17.00 · Expires 2029-03-06	Direct	Reported balance After 2024-05-31 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2024-05-31 · Disposition to issuer · Disposed 81,967 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, with a per share exercise price that was less than the Merger Consideration, was cancelled and converted into the right to receive a cash amount, without interest and less any applicable withholding taxes, equal to the product of (i) the aggregate number of shares of Common Stock underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option.
Performance Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	Reported balance After 2024-05-31 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2024-05-31 · Disposition to issuer · Disposed 100,810 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each RSU subject to performance-based vesting conditions ("PSU") outstanding immediately prior to the Effective Time, whether vested or unvested, was canceled and converted into the right to receive a cash amount, without interest and less any applicable withholding taxes, equal to the product of (i) the aggregate number of shares of Common Stock underlying such PSU (assuming attainment of (A) the actual level of performance for performance metrics for which the relevant performance period had been completed as of the Effective Time and (B) the maximum level of performance under the terms of the applicable award agreement as in effect on the date of the Merger Agreement for performance metrics for which the relevant performance period had not been completed as of the Effective Time) and (ii) the Merger Consideration. F5: (Continued from Footnote 4) The amount reported represents PSUs for which performance was deemed achieved assuming attainment of maximum level of performance.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports the disposition of securities pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 4, 2024, by and among the Issuer, Johnson & Johnson ("J&J"), and Sweep Merger Sub, Inc., a wholly owned subsidiary of J&J ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), effective as of the effective time of the Merger (the "Effective Time"), with the Issuer surviving the Merger as a wholly owned subsidiary of J&J. As a result of the Merger, at the Effective Time, each outstanding share of common stock, par value $0.001 per share, of the Issuer ("Common Stock") outstanding immediately prior to the Effective Time (excluding Excluded Shares and any Dissenting Company Shares, each as defined in the Merger Agreement) was automatically converted into the right to receive $335.00 in cash (the "Merger Consideration"),

F2: (Continued from Footnote 1) without interest and less any applicable withholding taxes. Additionally, pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit ("RSU") outstanding immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive a cash amount, without interest and less any applicable withholding taxes, equal to the product of (i) the aggregate number of shares of Common Stock underlying such RSU immediately prior to the Effective Time and (ii) the Merger Consideration.

F3: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, with a per share exercise price that was less than the Merger Consideration, was cancelled and converted into the right to receive a cash amount, without interest and less any applicable withholding taxes, equal to the product of (i) the aggregate number of shares of Common Stock underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option.

F4: Pursuant to the Merger Agreement, at the Effective Time, each RSU subject to performance-based vesting conditions ("PSU") outstanding immediately prior to the Effective Time, whether vested or unvested, was canceled and converted into the right to receive a cash amount, without interest and less any applicable withholding taxes, equal to the product of (i) the aggregate number of shares of Common Stock underlying such PSU (assuming attainment of (A) the actual level of performance for performance metrics for which the relevant performance period had been completed as of the Effective Time and (B) the maximum level of performance under the terms of the applicable award agreement as in effect on the date of the Merger Agreement for performance metrics for which the relevant performance period had not been completed as of the Effective Time) and (ii) the Merger Consideration.

F5: (Continued from Footnote 4) The amount reported represents PSUs for which performance was deemed achieved assuming attainment of maximum level of performance.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
May 15, 2020 Filed May 19, 2020 16:14 UTC	Shockwave Medical, Inc. SWAV · Entity 90374	SaleCommon Stock	19,936	$42.38	$844,921.57	Disclosure SEC source: 0000950103-20-009822 · dp128403_4-godshall.xml · nonDerivative · entry 4 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,359 F1 · kind: This exercise and all sale transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 9/6/2019. F4 · price: The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $42.13 to $42.83. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document
May 15, 2020 Filed May 19, 2020 16:14 UTC	Shockwave Medical, Inc. SWAV · Entity 90374	SaleCommon Stock	4,000	$41.64	$166,568.00	Disclosure SEC source: 0000950103-20-009822 · dp128403_4-godshall.xml · nonDerivative · entry 3 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,295 F1 · kind: This exercise and all sale transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 9/6/2019. F3 · price: The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $41.11 to $42.07. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document
May 15, 2020 Filed May 19, 2020 16:14 UTC	Shockwave Medical, Inc. SWAV · Entity 90374	SaleCommon Stock	6,064	$40.75	$247,103.76	Disclosure SEC source: 0000950103-20-009822 · dp128403_4-godshall.xml · nonDerivative · entry 2 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,295 F1 · kind: This exercise and all sale transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 9/6/2019. F2 · price: The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $40.11 to $41.10. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document
May 15, 2020 Filed May 19, 2020 16:14 UTC	Shockwave Medical, Inc. SWAV · Entity 90374	Exercise / conversionCommon Stock	30,000	$3.42	$102,480.00	Disclosure SEC source: 0000950103-20-009822 · dp128403_4-godshall.xml · nonDerivative · entry 1 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,359 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise and all sale transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 9/6/2019. Read SEC document
April 24, 2020 Filed Apr 27, 2020 18:05 UTC	Shockwave Medical, Inc. SWAV · Entity 90374	Tax withholdingCommon Stock	1,841	$39.48	$72,682.68	Disclosure SEC source: 0000950103-20-008194 · dp126841_4-godshall.xml · nonDerivative · entry 1 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,359 Read SEC document
February 28, 2020 Filed Mar 3, 2020 18:06 UTC	EyePoint, Inc. EYPT · Entity 5702	GrantStock Option (Right to Buy) · Derivative	33,500	$0.00 Strike: $1.29	$0.00	Disclosure SEC source: 0001562180-20-002049 · primarydocument.xml · derivative · entry 2 Godshall Douglas Evan · CIK 0001404227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,500 Underlying: Common Stock · 33,500 shares Expires 2030-02-28 Read SEC document
February 28, 2020 Filed Mar 3, 2020 18:06 UTC	EyePoint, Inc. EYPT · Entity 5702	GrantRestricted Stock Units · Derivative	19,000	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001562180-20-002049 · primarydocument.xml · derivative · entry 1 Godshall Douglas Evan · CIK 0001404227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,000 Underlying: Common Stock · 19,000 shares Expires not disclosed F1 · derivative.expiration_date: Will fully vest on the one-year anniversary of the grant date. Read SEC document
February 18, 2020 Filed Feb 19, 2020 20:47 UTC	Shockwave Medical, Inc. SWAV · Entity 90374	Exercise / conversionStock Option (Right to Buy) · Derivative	30,000	$0.00 Strike: $3.42	$0.00	Disclosure SEC source: 0000950103-20-002994 · dp121624_4-godshall.xml · derivative · entry 5 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,124,799 Underlying: Common Stock · 30,000 shares Expires 2027-05-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise and all sale transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 9/6/2019. F4 · derivative.exercise_date: Twenty-Five percent of the shares subject to this option vested on 5/9/18 and the balance of the shares are scheduled to vest in equal monthly installments thereafter for 36 months. Read SEC document
February 18, 2020 Filed Feb 19, 2020 20:47 UTC	Shockwave Medical, Inc. SWAV · Entity 90374	GrantCommon Stock	84,200	$0.00	$0.00	Disclosure SEC source: 0000950103-20-002994 · dp121624_4-godshall.xml · nonDerivative · entry 4 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,200 Read SEC document
February 18, 2020 Filed Feb 19, 2020 20:47 UTC	Shockwave Medical, Inc. SWAV · Entity 90374	SaleCommon Stock	13,183	$43.75	$576,753.61	Disclosure SEC source: 0000950103-20-002994 · dp121624_4-godshall.xml · nonDerivative · entry 3 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 F1 · kind: This exercise and all sale transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 9/6/2019. F3 · price: The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $43.45 to $44.04. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document
February 18, 2020 Filed Feb 19, 2020 20:47 UTC	Shockwave Medical, Inc. SWAV · Entity 90374	SaleCommon Stock	16,817	$42.82	$720,171.21	Disclosure SEC source: 0000950103-20-002994 · dp121624_4-godshall.xml · nonDerivative · entry 2 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,183 F1 · kind: This exercise and all sale transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 9/6/2019. F2 · price: The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $42.39 to $43.36. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document
February 18, 2020 Filed Feb 19, 2020 20:47 UTC	Shockwave Medical, Inc. SWAV · Entity 90374	Exercise / conversionCommon Stock	30,000	$3.42	$102,480.00	Disclosure SEC source: 0000950103-20-002994 · dp121624_4-godshall.xml · nonDerivative · entry 1 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise and all sale transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 9/6/2019. Read SEC document
November 21, 2019 Filed Nov 22, 2019 17:09 UTC	Shockwave Medical, Inc. SWAV · Entity 90374	Exercise / conversionStock Option (Right to Buy) · Derivative	30,000	$0.00 Strike: $3.42	$0.00	Disclosure SEC source: 0000950103-19-015812 · dp116218_4-godshall.xml · derivative · entry 4 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,154,799 Underlying: Common Stock · 30,000 shares Expires 2027-05-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Twenty-Five percent of the shares subject to this option vested on 5/9/18 and the balance of the shares are scheduled to vest in equal monthly installments thereafter for 36 months. Read SEC document
November 21, 2019 Filed Nov 22, 2019 17:09 UTC	Shockwave Medical, Inc. SWAV · Entity 90374	SaleCommon Stock	400	$37.88	$15,152.00	Disclosure SEC source: 0000950103-19-015812 · dp116218_4-godshall.xml · nonDerivative · entry 3 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 F3 · price: The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $37.87 to $37.89. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document
November 21, 2019 Filed Nov 22, 2019 17:09 UTC	Shockwave Medical, Inc. SWAV · Entity 90374	SaleCommon Stock	29,600	$37.42	$1,107,489.92	Disclosure SEC source: 0000950103-19-015812 · dp116218_4-godshall.xml · nonDerivative · entry 2 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,400 F2 · price: The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $36.87 to $37.80. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document
November 21, 2019 Filed Nov 22, 2019 17:09 UTC	Shockwave Medical, Inc. SWAV · Entity 90374	Exercise / conversionCommon Stock	30,000	$3.42	$102,480.00	Disclosure SEC source: 0000950103-19-015812 · dp116218_4-godshall.xml · nonDerivative · entry 1 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 9/6/2019. Read SEC document
June 25, 2019 Filed Jun 27, 2019 16:51 UTC	EyePoint, Inc. EYPT · Entity 5702	GrantStock Option (Right to Buy) · Derivative	40,000	$0.00 Strike: $2.65	$0.00	Disclosure SEC source: 0001562180-19-003665 · primarydocument.xml · derivative · entry 1 Godshall Douglas Evan · CIK 0001404227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2029-02-21 Read SEC document
June 21, 2019 Filed Jun 24, 2019 16:29 UTC	EyePoint, Inc. EYPT · Entity 5702	Exercise / conversionDeferred Stock Units · Derivative	6,667	$0.00	$0.00	Disclosure SEC source: 0001562180-19-003627 · primarydocument.xml · derivative · entry 2 Godshall Douglas Evan · CIK 0001404227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,667 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: On June 21, 2018, the reporting person was granted 6,667 DSUs. The DSUs vested in full on June 21, 2019 and will be settled solely in shares of the Company's common stock upon the earliest to occur of: (i) the reporting person's termination of service on the Company's Board of Directors and (ii) the occurrence of a "change in control" (as defined in the applicable award agreement) that constitutes a "change in the ownership or effective control of" the Company or "a change in the ownership of a substantial portion of the assets of" the Company, in each case, as determined under Section 409A of the Internal Revenue Code of 1986, as amended, and the regulations issued thereunder. F2 · derivative.exercise_date: On June 21, 2018, the reporting person was granted 6,667 DSUs. The DSUs vested in full on June 21, 2019 and will be settled solely in shares of the Company's common stock upon the earliest to occur of: (i) the reporting person's termination of service on the Company's Board of Directors and (ii) the occurrence of a "change in control" (as defined in the applicable award agreement) that constitutes a "change in the ownership or effective control of" the Company or "a change in the ownership of a substantial portion of the assets of" the Company, in each case, as determined under Section 409A of the Internal Revenue Code of 1986, as amended, and the regulations issued thereunder. F2 · derivative.expiration_date: On June 21, 2018, the reporting person was granted 6,667 DSUs. The DSUs vested in full on June 21, 2019 and will be settled solely in shares of the Company's common stock upon the earliest to occur of: (i) the reporting person's termination of service on the Company's Board of Directors and (ii) the occurrence of a "change in control" (as defined in the applicable award agreement) that constitutes a "change in the ownership or effective control of" the Company or "a change in the ownership of a substantial portion of the assets of" the Company, in each case, as determined under Section 409A of the Internal Revenue Code of 1986, as amended, and the regulations issued thereunder. Read SEC document
June 21, 2019 Filed Jun 24, 2019 16:29 UTC	EyePoint, Inc. EYPT · Entity 5702	Exercise / conversionCommon Stock	6,667	$0.00	$0.00	Disclosure SEC source: 0001562180-19-003627 · primarydocument.xml · nonDerivative · entry 1 Godshall Douglas Evan · CIK 0001404227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,167 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents vesting of deferred stock units ("DSUs") previously awarded to the reporting person, with each deferred stock unit representing the right to receive one share of the common stock of EyePoint Pharmaceuticals, Inc. (the "Company"). Read SEC document
April 24, 2019 Filed Jul 16, 2019 17:51 UTC	Shockwave Medical, Inc. SWAV · Entity 90374	GrantCommon stock	16,000	$0.00	$0.00	Disclosure SEC source: 0000950103-19-009372 · dp109810_4-godshall.xml · nonDerivative · entry 1 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 Read SEC document
March 29, 2019 Filed Apr 1, 2019 08:20 UTC	EyePoint, Inc. EYPT · Entity 5702	PurchaseCommon Stock	17,000	$1.75	$29,784.00	Disclosure SEC source: 0001562180-19-002053 · primarydocument.xml · nonDerivative · entry 1 Godshall Douglas Evan · CIK 0001404227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,500 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.75 to $1.77. The reporting person undertakes to provide EyePoint Pharmaceuticals Inc., any security holder of EyePoint Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document
March 06, 2019 Filed Mar 8, 2019 16:48 UTC	Shockwave Medical, Inc. SWAV · Entity 90374	GrantStock Options (Right to Buy) · Derivative	81,967	$0.00 Strike: $17.00	$0.00	Disclosure SEC source: 0000950103-19-003228 · dp103550_4-godshall.xml · derivative · entry 1 Godshall Douglas Evan · CIK 0001404227 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,967 Underlying: Common Stock · 81,967 shares Expires 2029-03-06 F1 · derivative.exercise_date: 1/48th of the options shall vest each month beginning on March 11, 2019 until 100% of the options have vested Read SEC document
September 19, 2018 Filed Sep 21, 2018 16:19 UTC	IMMUNIC, INC. VTL · Entity 6306	SaleCommon Stock	69,375	$0.35	$24,191.06	Disclosure SEC source: 0001280776-18-000091 · wf-form4_153756112908197.xml · nonDerivative · entry 1 Godshall Douglas Evan · CIK 0001404227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.34 to $0.35. The reporting person undertakes to provide Vital Therapies, Inc., any security holder of Vital Therapies, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price range set forth in this footnote (1) to this Form 4. Read SEC document
June 27, 2018 Filed Jun 29, 2018 16:00 UTC	EyePoint, Inc. EYPT · Entity 5702	Exercise / conversionDeferred Stock Units · Derivative	12,500	$0.00	$0.00	Disclosure SEC source: 0000899243-18-018708 · doc4.xml · derivative · entry 2 Godshall Douglas Evan · CIK 0001404227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: On December 15, 2017, the reporting person was granted 12,500 DSUs. The DSUs vested in full on June 27, 2018 and will be settled solely in shares of the Company's common stock upon the earliest to occur of: (i) the reporting person's termination of service on the Company's Board of Directors and (ii) the occurrence of a "change in control" (as defined in the applicable award agreement) that constitutes a "change in the ownership or effective control of" the Company or "a change in the ownership of a substantial portion of the assets of" the Company, in each case, as determined under Section 409A of the Internal Revenue Code of 1986, as amended, and the regulations issued thereunder. F2 · derivative.exercise_date: On December 15, 2017, the reporting person was granted 12,500 DSUs. The DSUs vested in full on June 27, 2018 and will be settled solely in shares of the Company's common stock upon the earliest to occur of: (i) the reporting person's termination of service on the Company's Board of Directors and (ii) the occurrence of a "change in control" (as defined in the applicable award agreement) that constitutes a "change in the ownership or effective control of" the Company or "a change in the ownership of a substantial portion of the assets of" the Company, in each case, as determined under Section 409A of the Internal Revenue Code of 1986, as amended, and the regulations issued thereunder. F2 · derivative.expiration_date: On December 15, 2017, the reporting person was granted 12,500 DSUs. The DSUs vested in full on June 27, 2018 and will be settled solely in shares of the Company's common stock upon the earliest to occur of: (i) the reporting person's termination of service on the Company's Board of Directors and (ii) the occurrence of a "change in control" (as defined in the applicable award agreement) that constitutes a "change in the ownership or effective control of" the Company or "a change in the ownership of a substantial portion of the assets of" the Company, in each case, as determined under Section 409A of the Internal Revenue Code of 1986, as amended, and the regulations issued thereunder. Read SEC document
June 27, 2018 Filed Jun 29, 2018 16:00 UTC	EyePoint, Inc. EYPT · Entity 5702	Exercise / conversionCommon Stock	12,500	$0.00	$0.00	Disclosure SEC source: 0000899243-18-018708 · doc4.xml · nonDerivative · entry 1 Godshall Douglas Evan · CIK 0001404227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents vesting of deferred stock units ("DSUs") previously awarded to the reporting person, with each deferred stock unit representing the right to receive one share of the common stock of EyePoint Pharmaceuticals, Inc. (the "Company"). Read SEC document
June 21, 2018 Filed Jun 26, 2018 14:12 UTC	EyePoint, Inc. EYPT · Entity 5702	GrantDeferred Stock Units · Derivative	6,667	$0.00	$0.00	Disclosure SEC source: 0000899243-18-018095 · doc4.xml · derivative · entry 2 Godshall Douglas Evan · CIK 0001404227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,667 Underlying: Common Stock · 6,667 shares Expires not disclosed F1 · derivative.exercise_price: Each deferred stock unit represents the right to receive one share of the common stock of EyePoint Pharmaceuticals, Inc. (the "Company"). F2 · derivative.expiration_date: Subsequent to the vesting of the deferred stock units, the deferred stock units will be settled in shares of the Company's common stock upon the earliest to occur of: (i) the reporting person's termination of service on the Company's Board of Directors and (ii) the occurrence of a "change in control" (as defined in the applicable award agreement) that constitutes a "change in the ownership or effective control of" the Company or "a change in the ownership of a substantial portion of the assets of" the Company, in each case, as determined under Section 409A of the Internal Revenue Code of 1986, as amended, and the regulations issued thereunder. Read SEC document
June 21, 2018 Filed Jun 26, 2018 14:12 UTC	EyePoint, Inc. EYPT · Entity 5702	GrantEmployee Stock Option (right to buy) · Derivative	26,667	$0.00 Strike: $1.95	$0.00	Disclosure SEC source: 0000899243-18-018095 · doc4.xml · derivative · entry 1 Godshall Douglas Evan · CIK 0001404227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,667 Underlying: Common Stock · 26,667 shares Expires 2028-06-21 Read SEC document
May 23, 2018 Filed May 25, 2018 16:07 UTC	IMMUNIC, INC. VTL · Entity 6306	GrantStock Option (right to buy) · Derivative	29,538	$0.00 Strike: $6.10	$0.00	Disclosure SEC source: 0001280776-18-000040 · wf-form4_152727884006375.xml · derivative · entry 1 Godshall Douglas Evan · CIK 0001404227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,538 Underlying: Common Stock · 29,538 shares Expires 2028-05-22 F1 · derivative.exercise_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the 2014 Equity Incentive Plan) through the vesting date, 100% of the shares will vest upon the earlier of the one (1) year anniversary of the Grant Date or the day prior to the Company's 2019 annual meeting of stockholders. Read SEC document
December 15, 2017 Filed Dec 19, 2017 16:08 UTC	EyePoint, Inc. PSDV · Entity 5702	GrantDeferred Stock Units · Derivative	12,500	$0.00	$0.00	Disclosure SEC source: 0000899243-17-029161 · doc4.xml · derivative · entry 2 Godshall Douglas Evan · CIK 0001404227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires not disclosed F1 · derivative.exercise_price: Each deferred stock unit represents the right to receive one share of the common stock of pSivida Corp. (the "Company"). F2 · derivative.expiration_date: Subsequent to the vesting of the deferred stock units, the deferred stock units will be settled in shares of the Company's common stock upon the earliest to occur of: (i) the reporting person's termination of service on the Company's Board of Directors and (ii) the occurrence of a "change in control" (as defined in the applicable award agreement) that constitutes a "change in the ownership or effective control of" the Company or "a change in the ownership of a substantial portion of the assets of" the Company, in each case, as determined under Section 409A of the Internal Revenue Code of 1986, as amended, and the regulations issued thereunder. Read SEC document
December 15, 2017 Filed Dec 19, 2017 16:08 UTC	EyePoint, Inc. PSDV · Entity 5702	GrantEmployee Stock Option (right to buy) · Derivative	20,000	$0.00 Strike: $1.77	$0.00	Disclosure SEC source: 0000899243-17-029161 · doc4.xml · derivative · entry 1 Godshall Douglas Evan · CIK 0001404227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2027-06-27 Read SEC document
May 23, 2017 Filed May 25, 2017 17:32 UTC	IMMUNIC, INC. VTL · Entity 6306	GrantStock Option (right to buy) · Derivative	45,022	$0.00 Strike: $3.20	$0.00	Disclosure SEC source: 0001280776-17-000047 · wf-form4_149574792815403.xml · derivative · entry 1 Godshall Douglas Evan · CIK 0001404227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,022 Underlying: Common Stock · 45,022 shares Expires 2027-05-22 F1 · derivative.exercise_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the 2014 Equity Incentive Plan) through the vesting date, 100% of the shares will vest upon the earlier of the one (1) year anniversary from May 23, 2017 or the day prior to the Company's 2018 annual meeting of stockholders. Read SEC document
December 12, 2016 Filed Dec 14, 2016 12:59 UTC	EyePoint, Inc. PSDV · Entity 5702	GrantEmployee Stock Option (right to buy) · Derivative	20,000	$0.00 Strike: $3.49	$0.00	Disclosure SEC source: 0000899243-16-035514 · doc4.xml · derivative · entry 1 Godshall Douglas Evan · CIK 0001404227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2026-07-21 Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.